Regeneron Pharmaceuticals (REGN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist

701.850
-6.400-0.90%

Close Dec 20 16:00 ET

706.330
+4.480+0.64%

Post 20:01 ET

77.13BMarket Cap17.36P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
Moomoo NewsDec 20 13:31 ET · Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Moomoo NewsDec 20 13:31 ET · Ratings
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Moomoo NewsDec 20 13:31 ET · Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Kevin TraversDec 20 10:29 ET
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
MT NewswiresDec 20 10:24 ET · Ratings
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Seeking AlphaDec 19 13:16 ET

Comments

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

NathanRobert

Nov 13 15:03

5 Quality Stocks That Are Undervalued

🔥 We go over 5 stocks that look undervalued, i show you the numbers for yourself, i own 1 of the stocks on the list, but i try to go over stocks you’ve probably never heard of before! LMK ur thoughts :)
$Hershey (HSY.US)$ $Celsius Holdings (CELH.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Yelp Inc (YELP.US)$ $Innovative Industrial Properties Inc (IIPR.US)$

https://youtu.be/4qd-58cBqi4

From YouTube

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Heat List

Overall

No Data

Investment Theme

Infectious Disease

Intraday+0.78%